The problem is greater than 50% of the people who have heart attacks, have normal lipids, why? Inflammation perhaps. V could be a great stand alone drug or preventative medicine for slowing or even reversing CVD.
I'm sure there are some thoughts about the possibility of a stand alone CVOT Amarin managment! Like jupiter probably base enrollment on inflammation markers rather than LDL-C levels.
Of course this will be kept under wraps until a design is well underway.
STS - you might be correct that BP won't want to run a long term study with V alone - without a statin. But, don't you think it's a crucial question - will Vascepa alone cause a significant decrease in CVD? I do
Aspirin studies are run all the time - it's generic. Plenty of statin studies were run with generics. Academics and the NIH will run studies using generics if they answer important questions. We may not get an answer anytime soon but if some folks on this board are correct AMRN could even make $ in a generic world.
News 
Market Data 
Discover 
AI
